Gilead Sciences | GILD - Eigenkapital Und Reserven

Aktienkurs
141.11
Täglich Wechseln
-0.18 -0.13%
Monatlich
-6.80%
Jährlich
33.29%
Q1 Prognose
140.61




Eigenkapital Und Reserven Veränderung Datum
AbbVie USD -3.27B 628M 2025-12
Agios Pharmaceuticals USD 1.19B 91.22M 2025-12
ALKERMES USD 1.82B 85.86M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amgen USD 8.66B 961M 2025-12
Biogen USD 18.21B 573.5M 2025-09
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
GlaxoSmithKline GBP 16.38B 229M 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Incyte USD 5.17B 516.28M 2025-12
J&J USD 78.47B 0 2025-09
Merck USD 51.85B 2.79B 2025-09
Moderna USD 8.65B 680M 2025-12
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Novartis USD 46.13B 1.38B 2025-12
Pfizer USD 92.8B 4.11B 2025-09
PTC Therapeutics USD -205.31M 49.56M 2025-12
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 71.71B 1.55B 2025-12
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
United Therapeutics USD 7.1B 506M 2025-12
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12